Showing 3691-3700 of 5773 results for "".
- Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments Intraocular Dyeshttps://modernod.com/news/bausch-lomb-named-exclusive-global-distributor-of-alfa-instruments-intraocular-dyes/2481060/Bausch + Lomb and Alfa Instruments announced that the companies have entered into an exclusive distribution agreement under which Bausch + Lomb will distribute and commercialize Alfa Instruments' line of surgical intraocular dyes—Vitreocare—globally with the exception of Italy, wh
- Vyluma Completes Last Patient Visit for Phase 3 CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-completes-last-patient-visit-for-primary-analysis-of-pivotol-phase-iii-champ-study-evaluating-nvk002-for-the-treatment-of-myopia-progression-in-children/2481059/Vyluma announced that the last patient visit has been completed for the primary analysis of the pivotal phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with the FDA, to evaluate whether NVK002 eye drops are safe and eff
- Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseaseshttps://modernod.com/news/opus-genetics-hosts-inaugural-patient-advocacy-outreach-webinar-on-inherited-retinal-diseases/2481058/Opus Genetics announced the release of the first patient advocacy outreach webinar featuring presentations by Opus leadership: Ben Yerxa, PhD, and CEO of Opus; Ash Jayagopal, PhD, and chief scientific officer; Joe Schachle, COO; and Jennifer Hunt, chief development officer. The recorded webinar,
- Lucentis Biosimilar Ranivisio Receives Marketing Authorization from European Commissionhttps://modernod.com/news/european-commission-grants-marketing-authorization-for-ranivisio-for-amd/2481057/Teva Pharmaceuticals announced that it has received marketing authorization from the European Commission for Ranivisio (ranibizumab), a biosimilar of Lucentis. The authorization includes all five indications for which Lucentis is authorized in adults.
- Outlook Therapeutics Resubmits Biologics License Application to FDA for Wet AMD Drug Candidate ONS-5010https://modernod.com/news/outlook-therapeutics-re-submits-biologics-license-application-for-ons-5010-as-a-treatment-for-wet-amd-to-the-fda/2481052/Outlook Therapeutics announced it has resubmitted its biologics license application (BLA) to the FDA for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD
- Bausch Health Continuing Process Toward Separating Bausch + Lombhttps://modernod.com/news/bausch-health-continuing-process-toward-separating-bausch-lomb/2481048/Bausch Health Companies announced it is moving toward separating Bausch + Lomb after transferring common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing wholly-owned unrestricted subsidiary of the company.
- Haag-Streit Opens New Surgical Microscope Production Site in Aesch, Switzerlandhttps://modernod.com/news/haag-streit-opens-new-surgical-microscope-production-site-in-aesch-switzerland/2481047/Haag-Streit announced the opening of a new state-of-the-art microscope production site in Aesch, Switzerland. In September 2021, Haag-Streit decided to reposition and focus solely on ophthalmology and the production and future development of the
- eSight and Marathon Medical Partner to Provide Sight Medical Devices to the US Department of Veterans Affairshttps://modernod.com/news/esight-and-marathon-medical-partner-to-provide-sight-medical-devices-to-the-us-department-of-veterans-affairs/2481043/Vision-enhancement platform eSight and Marathon Medical Corp., a SDVOSB (Service-Disabled Veteran Owned Small Business) certified distributor to veteran medical facilities across the United States, announced that the’ve partnered to provide eSight 4 assistive eyewear medical devices to
- Alcon to Acquire Aerie Pharmaceuticalshttps://modernod.com/news/alcon-to-acquire-aerie-pharmaceuticals/2481041/In another move to bolster its glaucoma portolio and expand its pharmaceutical offerings, Alcon announced it is acquiring Aerie Pharmaceuticals for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s lastest closing price. The transaction was a
- Sight Sciences Introduces SION—The First Bladeless Device Used in Goniotomyhttps://modernod.com/news/sight-sciences-introduces-the-sion-the-first-bladeless-device-used-in-goniotomy/2481040/Sight Sciences announced the launch of